Abstract: Disclosed is an article for use with apparatus for heating smokable material to volatilize at least one component of the smokable material. The article includes a smokable material, such as tobacco, and a heater for heating the smokable material. The heater comprises heating material that is heatable by penetration with a varying magnetic field. The heating material has a Curie point temperature that is less than the combustion temperature of the smokable material.

Abstract: Disclosed is an article for use with apparatus for heating smokable material to volatilize at least one component of the smokable material. The article comprises smokable material, such as tobacco, and a heater for heating the smokable material. The heater comprises heating material that is heatable by penetration with a varying magnetic field. The heating material has a Curie point temperature that is less than the combustion temperature of the smokable material.

Abstract: Disclosed is an article for use with apparatus for heating smokable material to volatilize at least one component of the smokable material. The article includes a cavity for receiving smokable material, and a coil of heating material that is heatable by penetration with a varying magnetic field to heat the cavity. Also disclosed is a system including the article and apparatus. The apparatus has an interface for cooperating with the article, and a magnetic field generator. The magnetic field generator includes a coil for generating a varying magnetic field for penetrating the coil of the article when the interface is cooperating with the article. An impedance of the coil of the magnetic field generator is equal, or substantially equal, to an impedance of the coil of the article.

Abstract: Metal chalcogenides, and methods of making and using metal chalcogenides, are disclosed herein. Metal chalcogenides can be prepared by heating suitable copper, zinc, and/or tin compounds selected from the group consisting of chalcogenocarbamates, dichalcogenocarbamates, mercaptides, thiiocarbonates, trithiocarbonates, and combinations thereof (e.g., copper, zinc, and/or tin dichalcogenocarbamates) under conditions effective to form metal can be used, for example, to prepare solar cells.

Abstract: A tampon pledget includes crosslinked cellulose fibers having microstructures treated to provide improved absorbency and higher wet strength. The fibers are treated with a crosslinking agent to provide at least one of a molecular weight between crosslinks of from about 10 to 200 and a degree of crystallinity of from about 25% to 75%. The crosslinking agent includes citric acid in 1% by weight. The crosslinking agent may further include sodium hypophosphite in 1% by weight. In another embodiment, the crosslinking agent may be a difunctional agent including a glyoxal or a glyoxal-derived resin. In still another embodiment, the crosslinking agent is a multifunctional agent including a cyclic urea, glyoxal, polyol condensate. The crosslinking agent is added in an amount from about 0.001% to 20% by weight based on a total weight of cellulose fibers to be treated and, preferably, in an amount of about 5% by weight.

Abstract: The present invention provides devices and methods for micro-scale simulated moving bed chromatography (SMB) for continuous preparation of analytic quantities of highly pure fractions of target molecules. The present apparatus and method of the invention is adapted in a preferred embodiment to separations by affinity chromatography involving three discontinuous liquid flow loops. An alternative embodiment of affinity chromatography utilizes standard SMB operating under isocratic conditions.

Abstract: The disclosed airbag device for a vehicle may comprise an airbag and at least one connection member. The airbag may have first and second side surfaces, wherein the first side surface has upper and lower ends. The at least one connection member may connect the lower end of the first side surface to an intermediate position on the first side surface located between the upper and lower ends of the first side surface.

Abstract: A tampon pledget includes crosslinked cellulose fibers having microstructures treated to provide improved absorbency and higher wet strength. The fibers are treated with a crosslinking agent to provide at least one of a molecular weight between crosslinks of from about 10 to 200 and a degree of crystallinity of from about 25% to 75%. The crosslinking agent includes citric acid in 1% by weight. The crosslinking agent may further include sodium hypophosphite in 1% by weight. In another embodiment, the crosslinking agent may be a difunctional agent including a glyoxal or a glyoxal-derived resin. In still another embodiment, the crosslinking agent is a multifunctional agent including a cyclic urea, glyoxal, polyol condensate. The crosslinking agent is added in an amount from about 0.001% to 20% by weight based on a total weight of cellulose fibers to be treated and, preferably, in an amount of about 5% by weight.

Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: The present invention provides devices and methods for micro-scale simulated moving bed chromatography (SMB) for continuous preparation of analytic quantities of highly pure fractions of target molecules. The present apparatus and method of the invention is adapted in a preferred embodiment to separations by affinity chromatography involving three discontinuous liquid flow loops. An alternative embodiment of affinity chromatography utilizes standard SMB operating under isocratic conditions.

Abstract: The present invention provides devices and methods for micro-scale simulated moving bed chromatography (SMB) for continuous preparation of analytic quantities of highly pure fractions of target molecules. The present apparatus and method of the invention is adapted in a preferred embodiment to separations by affinity chromatography involving three discontinuous liquid flow loops. An alternative embodiment of affinity chromatography utilizes standard SMB operating under isocratic conditions.

Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: The present invention relates to X-ray crystallography studies of a JAK2 kinase domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Abstract: Methods using compounds of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof to treat protein kinase-associated disease states is described.

Abstract: The present invention relates to X-ray crystallography studies of a JAK2 kinase domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Abstract: The present invention relates to X-ray crystallography studies of a JAK2 kinase domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Abstract: The present invention relates to X-ray crystallography studies of a JAK2 kinase domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Abstract: The present invention relates to X-ray crystallography studies of a human Janus Kinase 2 (JAK2) domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.

Abstract: The present invention relates to X-ray crystallography studies of a JAK2 kinase domain. More particularly, it relates to the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention further relates to the use of the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins and to compounds that could be used for the treatment of diseases mediated by inappropriate JAK2 activity.